Intra-Cellular Therapies (NasdaqGS:ITCI) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold Intra-Cellular Therapies to reach your target.
Hmm, we can't give any reliable projection for Intra-Cellular Therapies's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.
None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!
| Advantages | Disadvantages | Neutral |
|---|---|---|
| None. |
|
|
| ITCI Price (Intra-Cellular Therapies stock price per share) |
$0.00 | |
| PE Ratio versus Sector | 100% lower than other Healthcare stocks | |
| PE Ratio versus Industry | 100% lower than other Drug Manufacturers - General stocks | |
| Free Cash Flow Jitter | 52% |
No open-market insider buys or sells are recorded for the last 12 months.
Open-market buys and sells reported by Intra-Cellular Therapies's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2024-12-05 | Mates Sharon (Chairman and CEO) | Sell | 1,534 | $84.69 |
| 2024-12-05 | Mates Sharon (Chairman and CEO) | Sell | 50,163 | $84.06 |
| 2024-12-04 | Mates Sharon (Chairman and CEO) | Sell | 27,667 | $85.62 |
| 2024-12-04 | Mates Sharon (Chairman and CEO) | Sell | 23,333 | $86.00 |
| 2024-11-13 | Halstead Michael (President) | Sell | 13,371 | $88.17 |
| 2024-11-13 | Halstead Michael (President) | Sell | 5,343 | $88.92 |
| 2024-11-12 | Halstead Michael (President) | Sell | 1,648 | $90.89 |
| 2024-11-12 | Halstead Michael (President) | Sell | 6,116 | $89.63 |
| 2024-11-12 | Halstead Michael (President) | Sell | 15,105 | $88.72 |
| 2024-08-30 | Mates Sharon (Chairman and CEO) | Sell | 28,203 | $72.73 |
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
How to read this: free cash flow in plain terms, free cash flow jitter.
How to read this: what free cash flow is, why earnings matter.
Net income was negative in all 13 fiscal years from 2012 to 2024, so no ratio of operating cash flow to net income is shown. Operating cash flow totaled -$1,542 million over those years, against net income of -$1,678 million.
In 2024, net income was -$74.7 million and operating cash flow was -$73.2 million, so no ratio is shown for that year.
| Fiscal year | Net income (USD millions) | Operating cash flow (USD millions) | Capital expenditures (USD millions) | Operating cash flow / net income |
|---|---|---|---|---|
| 2012 | -16.6 | -18.9 | 0 | n/a |
| 2013 | -26.9 | -22.6 | 0 | n/a |
| 2014 | -30.7 | -22.8 | 0 | n/a |
| 2015 | -105 | -102 | 0.9 | n/a |
| 2016 | -116 | -91.3 | 0 | n/a |
| 2017 | -97.8 | -80.5 | 0.7 | n/a |
| 2018 | -155 | -118 | 0.4 | n/a |
| 2019 | -148 | -128 | 0.7 | n/a |
| 2020 | -227 | -230 | 0.3 | n/a |
| 2021 | -284 | -260 | 0.3 | n/a |
| 2022 | -256 | -270 | 0.8 | n/a |
| 2023 | -140 | -124 | 0.3 | n/a |
| 2024 | -74.7 | -73.2 | 0.3 | n/a |
How to read this: earnings and margins.
Revenue was $3.1 million in 2012 and $681 million in 2024, a compound annual growth rate of 56.7% over 12 years. The starting revenue was under 10% of the latest, so that rate comes from a small base and says little about recent growth.
Revenue rose 46.6% from 2023 to 2024.
Our estimated free cash flow was -$73.6 million in 2024, a negative margin of 10.8% of revenue, meaning the estimate was below zero. In 2012 the estimated margin was negative 607.5%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.
| Fiscal year | Revenue (USD millions) | Estimated free cash flow (USD millions) | Estimated free cash flow / revenue |
|---|---|---|---|
| 2012 | 3.1 | -18.9 | -607.5% |
| 2013 | 2.7 | -22.6 | -826.7% |
| 2014 | 0.6 | -22.8 | -3955.5% |
| 2015 | 0.1 | -103 | -112206.2% |
| 2016 | 0.3 | -91.5 | -27655.1% |
| 2017 | 0.2 | -80.8 | -32878.5% |
| 2019 | 0.1 | -129 | -212047.2% |
| 2020 | 22.8 | -230 | -1010.4% |
| 2021 | 83.8 | -260 | -310.3% |
| 2022 | 250 | -271 | -108.1% |
| 2023 | 464 | -125 | -26.8% |
| 2024 | 681 | -73.6 | -10.8% |
How to read this: how debt and assets are compared, the current ratio.
In 2024, cash and equivalents were $307 million against total liabilities of $218 million, or 140.5% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.
Total liabilities were 16.0% of total assets in 2024, compared with 14.3% in 2012, an increase of 1.7 percentage points.
Stockholders equity was $1,148 million in 2024, compared with $17 million in 2012, a rise of 6662.0%.
Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was -8.6% in 2024. Invested capital here is total assets less cash and current liabilities.
| Fiscal year | Total assets (USD millions) | Cash and equivalents (USD millions) | Total liabilities (USD millions) | Stockholders equity (USD millions) |
|---|---|---|---|---|
| 2012 | 19.8 | 15.6 | 2.8 | 17 |
| 2013 | 38.4 | 35.2 | 6.8 | 31.6 |
| 2014 | 131 | 61.3 | 10.6 | 121 |
| 2015 | 484 | 47.2 | 7.9 | 476 |
| 2016 | 389 | 48.6 | 13.4 | 376 |
| 2017 | 471 | 37.8 | 17 | 454 |
| 2018 | 357 | 54.9 | 39.5 | 318 |
| 2019 | 251 | 108 | 56.2 | 195 |
| 2020 | 717 | 60 | 60.5 | 657 |
| 2021 | 490 | 92.4 | 72 | 418 |
| 2022 | 755 | 149 | 98.7 | 656 |
| 2023 | 728 | 148 | 137 | 591 |
| 2024 | 1,367 | 307 | 218 | 1,148 |
We do not estimate a fair value for Intra-Cellular Therapies while its free cash flow growth is not positive, so there is no value comparison here.
Free cash flow was negative in every one of the 13 fiscal years we have for Intra-Cellular Therapies under its current filer.
Free cash flow is volatile from year to year, with a variability measure of 52%.
These numbers change when new filings or prices arrive, so treat this page as a snapshot and check the company's own filings.
Dividends are not in our data for Intra-Cellular Therapies.
How to read this: the price to earnings ratio.
Its trailing P/E ratio is 100% below the average for stocks in the Healthcare sector.
Its trailing P/E ratio is 100% below the average for stocks in the Drug Manufacturers - General industry.
A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.
These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Intra-Cellular Therapies, limited to companies whose pages we publish. The figures come from our latest data for each company.
| Company | Market cap (USD millions) | P/E | Dividend yield | Cash yield | Price versus our estimate |
|---|---|---|---|---|---|
| Intra-Cellular Therapies (ITCI) | - | - | - | - | - |
| Abbott Laboratories (ABT) | 178,390 | 38.4 | 2.4% | 1.9% | 49% above |
| Alkermes plc (ALKS) | 7,552 | - | - | 1.5% | 315% above |
| Amphastar Pharmaceuticals (AMPH) | 1,205 | 13.0 | - | 0.9% | 98% above |
| ANI Pharmaceuticals (ANIP) | 1,558 | 13.9 | - | - | 188% above |
| Bristol-Myers Squibb Company (BMY) | 120,192 | 13.0 | 4.3% | 1.2% | 85% above |
| Collegium Pharmaceutical (COLL) | 768 | 22.7 | - | - | 155% above |
Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.
Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.
Every fiscal year on this page is reported by one SEC filer, CIK 1567514.
Each figure on this page comes from that filer.
How to read this: understanding investment risk.
Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.
Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.
The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.
This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.
Read the filings yourself: ITCI annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.
Advertisement supports free stock analysis content.
Does Intra-Cellular Therapies have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to ITCI: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
What is the Difference Between Trading Stocks and Investing?
Why Do Companies Perform Stock Buybacks?
How Does Portfolio Churning Affect Your Returns?
How Do Tariffs Affect the Stock Market?
DCA vs Lump Sum: 155 Years of S&P 500 Historical Data
How to Invest $1000 in the Stock Market